Related Experiment Video
Updated: Jun 27, 2025

06:11
Therapy Testing in a Spheroid-based 3D Cell Culture Model for Head and Neck Squamous Cell Carcinoma
Published on: April 20, 2018
9.8K
Neighborhood-Level Disadvantage and Delayed Adjuvant Therapy in Head and Neck Cancer
Evan M Graboyes1,2, Joshua Lee Cagle1, Salma Ramadan3
1Department of Otolaryngology-Head and Neck Surgery, Medical University of South Carolina, Charleston.
JAMA Otolaryngology-- Head & Neck Surgery
|April 25, 2024
Summary
Neighborhood disadvantage increases delays in postoperative radiation therapy (PORT) for head and neck cancer patients. Addressing area deprivation is crucial for equitable cancer care delivery.
Area of Science:
- Oncology
- Public Health
- Health Services Research
Background:
- Timely postoperative radiation therapy (PORT) is crucial for head and neck squamous cell carcinoma (HNSCC) treatment outcomes.
- While individual socioeconomic status impacts PORT receipt, neighborhood-level disadvantage remains understudied.
- National guidelines recommend initiating PORT within 6 weeks of surgery for HNSCC.
Purpose of the Study:
- To investigate the association between neighborhood-level disadvantage and delays in receiving guideline-adherent PORT for HNSCC patients.
- To quantify the impact of area deprivation on the timeliness of postoperative radiation therapy.
Main Methods:
- Retrospective cohort study of 681 HNSCC patients undergoing surgery and PORT across 4 US academic medical centers (2018-2020).
- Area Deprivation Index (ADI) scores at the census block level were used to measure neighborhood disadvantage.
- Multivariable logistic regression and Cox models analyzed the association of ADI with PORT delay and time-to-PORT (TTP), adjusting for patient, clinical, and institutional factors.
Main Results:
- A significant PORT delay rate of 60.8% was observed.
- Higher Area Deprivation Index (ADI) scores were independently associated with increased odds of PORT delay (aOR, 1.32 per 25-point increase).
- Increasing ADI quartiles correlated with longer time-to-PORT, indicating a dose-dependent relationship.
Conclusions:
- Neighborhood-level disadvantage is a significant, independent factor contributing to delays in guideline-adherent PORT for HNSCC.
- These findings highlight the need for multilevel interventions to ensure equitable access to timely cancer treatment.
- Addressing area deprivation is essential for improving cancer care delivery and patient outcomes.
Related Concept Videos
Local Anesthetics: Adverse Effects
414
While local anesthetics are generally safe and well-tolerated, they can occasionally cause adverse effects that vary in severity. Local anesthetics can induce toxicity at two distinct levels. They can either produce local effects through direct contact with the neural elements or be absorbed into the bloodstream from the injection site, leading to systemic effects.
Once absorbed into the systemic circulation, local anesthetics can affect the organs that depend on the functioning of sodium...
Once absorbed into the systemic circulation, local anesthetics can affect the organs that depend on the functioning of sodium...
414
Targeted Cancer Therapies
7.6K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.6K
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
198
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
198

